Fetal tachycardia: causes, assessment and transplacental treatment

Fetal tachycardia is an unusually rapid fetal heart rate, generally defined as a sustained rate above 180 beats per minute. It may be a temporary response to maternal fever or medication, or a sign of a fetal cardiac arrhythmia that requires urgent specialist assessment. The clinical picture can change quickly, particularly when the rhythm is persistent.

The most important distinction is between sinus tachycardia and an abnormal re-entrant rhythm such as supraventricular tachycardia (SVT). Sinus tachycardia usually has a gradual onset and variable rate, while SVT often begins abruptly and remains very fast, commonly between 220 and 300 beats per minute. Atrial flutter is another important cause and may produce a slower ventricular rate with an atrial rate that is much higher.

Management aims to identify the rhythm, protect the fetus from heart failure, and treat the underlying maternal or fetal condition. When the pregnancy is too early for safe delivery or the fetus is unstable, medicines given to the mother can cross the placenta and treat the arrhythmia before birth.

Recognising an abnormal fetal heart rate

A rapid rate may be detected during routine antenatal surveillance, a presentation to hospital with reduced fetal movements, or an ultrasound examination. Short episodes can occur with fetal movement and are not automatically pathological. Concern rises when the tachycardia is sustained, regular, associated with hydrops, or accompanied by reduced variability and signs of cardiac dysfunction.

Maternal factors should be reviewed immediately. Fever, dehydration, anxiety, pain, hyperthyroidism, infection, anaemia, and medicines such as beta-agonists can increase the fetal heart rate. A maternal pulse and temperature help distinguish maternal sinus tachycardia from a primary fetal rhythm disorder. The fetal rate should be assessed with cardiotocography and, where available, detailed fetal echocardiography.

Ultrasound can show atrial and ventricular timing, atrioventricular conduction, ventricular function, valve regurgitation, cardiomegaly, and fluid accumulation. Hydrops fetalis, including ascites, pleural or pericardial effusion, and skin oedema, indicates significant compromise. The presence of hydrops usually makes treatment more urgent and can affect which medicine is likely to work.

Causes and diagnostic pathway

Fetal tachycardia has several possible causes. Sinus tachycardia may follow maternal infection, fever, thyrotoxicosis, hypoxia, anaemia, or exposure to stimulants and sympathomimetic drugs. Fetal anaemia related to parvovirus B19, red-cell alloimmunisation, fetomaternal haemorrhage, or twin-to-twin transfusion should be considered when ultrasound suggests increased middle cerebral artery peak systolic velocity.

Primary fetal arrhythmias include SVT, atrial flutter, atrial ectopic tachycardia, and less commonly ventricular tachycardia. SVT is often caused by an accessory atrioventricular pathway, allowing a rapid electrical circuit. Atrial flutter involves rapid atrial activity with variable conduction to the ventricles. The distinction matters because a medication that is effective for one rhythm may be less useful or carry unnecessary risk for another.

Assessment commonly includes a full maternal history, examination, blood tests, infection screening when indicated, thyroid function testing, and review of prescribed and non-prescribed medicines. Fetal echocardiography by a maternal-fetal medicine or paediatric cardiology team is central. Specialist review should occur promptly rather than relying on repeated routine monitoring when the rate is persistently elevated.

The historical FAOPS 2020 archive reflects the international focus on perinatal and neonatal medicine that brought specialists together in Tokyo before the meeting was cancelled during the COVID-19 pandemic. Its subject area remains relevant to Australian clinicians managing complex fetal cardiac and neonatal cases through multidisciplinary networks.

How medicines cross the placenta

Transplacental therapy treats the fetus indirectly. The pregnant patient receives an antiarrhythmic, which reaches the fetal circulation through the placenta. The dose must achieve a therapeutic fetal effect without causing clinically important maternal hypotension, bradycardia, conduction disturbance, or proarrhythmia.

Digoxin, flecainide, and sotalol are among the medicines used in specialist practice. The selection depends on the documented rhythm, gestational age, fetal ventricular function, presence of hydrops, maternal health, local protocols, and the experience of the treating team. There is no single regimen appropriate for every pregnancy.

These categories describe common clinical practice rather than a prescribing protocol. Evidence comes from observational studies, case series, pharmacology, and specialist consensus, so treatment should be directed by fetal medicine, cardiology, and pharmacy teams. Maternal consent should include the expected benefits, uncertainties, alternatives, and potential adverse effects.

Monitoring response and safety

Treatment usually involves serial fetal echocardiography and rhythm assessment, with attention to ventricular function, atrioventricular conduction, hydrops, and the rate of improvement. Cardiotocography can support surveillance later in gestation, although it cannot replace echocardiography for defining the rhythm mechanism. A falling rate and improved cardiac function are encouraging, but recurrence can occur if treatment is reduced too quickly.

Maternal monitoring is equally important. Depending on the drug, this may include an electrocardiogram, blood pressure, pulse, electrolytes, renal function, liver tests, and serum drug levels. Symptoms such as faintness, palpitations, breathlessness, visual disturbance, nausea, or chest discomfort require prompt clinical review. Medicines that prolong the QT interval should be used with careful attention to electrolyte abnormalities and other QT-prolonging drugs.

If hydrops is severe, transplacental treatment may take longer to work because placental transfer can be impaired. In selected cases, direct fetal therapy or delivery may be considered. Gestational age, lung maturity, fetal condition, availability of neonatal intensive care, and the likelihood of successful rhythm control all influence the decision. The safest plan is usually made in a tertiary centre with the capacity for emergency maternal and neonatal care.

Australian care and practical realities

In Australia, a suspected persistent fetal tachycardia may lead to referral from a community obstetrician, general practitioner, or regional maternity unit to a tertiary service in Sydney, Melbourne, Brisbane, Perth, Adelaide, or another specialist centre. Long travel distances can affect timing, accommodation, work, and family responsibilities, particularly for patients referred from rural and remote areas. Early coordination with the receiving hospital can reduce avoidable delays.

Medication access depends on hospital formularies, Therapeutic Goods Administration arrangements, pharmacy supply, and the clinical indication. A medicine used in a fetal cardiology protocol may require hospital dispensing, specialist approval, or careful coordination with a community pharmacy. Costs and availability can differ between public and private pathways, while Medicare arrangements do not remove the need to plan for travel, monitoring, and repeated appointments.

Communication should be culturally safe and suited to the family’s circumstances. Aboriginal and Torres Strait Islander families may prefer involvement of Aboriginal health workers or liaison officers, and professional interpreters should be used when English is not the patient’s first language. Telehealth can support follow-up for families in regional Australia, although urgent rhythm assessment still requires access to appropriate ultrasound and maternal monitoring.

Australian teams also need to plan around local referral customs: shared care may involve a local obstetric unit, a fetal medicine service, a paediatric cardiologist, a neonatologist, and a pharmacist. Written escalation instructions are valuable when a patient returns to a regional hospital. They should specify symptoms requiring urgent attendance, who to contact after hours, and where delivery should occur if the rhythm deteriorates.

Practical recommendations for clinical teams

A structured approach helps prevent the rapid fetal rate from being treated as an isolated cardiotocography finding. The clinical team should document the rhythm mechanism as clearly as possible, record baseline maternal observations, and establish how often fetal and maternal assessments will occur. Families benefit from plain-language explanations because treatment may continue for days or weeks and can involve uncertainty.

The following actions support safe, coordinated care:

• Confirm persistent tachycardia with targeted ultrasound and fetal echocardiography rather than relying on a single Doppler reading.
• Search for reversible maternal and fetal causes, including fever, thyroid disease, infection, anaemia, medication exposure, and fetal hypoxia.
• Involve maternal-fetal medicine, fetal or paediatric cardiology, neonatology, pharmacy, and the local maternity service early.
• Choose transplacental therapy according to the rhythm, fetal condition, hydrops status, maternal comorbidities, and current specialist protocol.
• Monitor maternal ECG, vital signs, renal function, electrolytes, and drug-specific toxicity throughout treatment.
• Give families a written plan covering warning symptoms, travel arrangements, medication timing, follow-up scans, and the proposed place of birth.
• Reassess the need for delivery or alternative intervention if the rhythm persists, hydrops progresses, or maternal toxicity develops.

Prompt recognition can turn a frightening ultrasound finding into a carefully managed perinatal pathway. Australian patients should be referred urgently to the nearest service with fetal cardiology or maternal-fetal medicine expertise, especially when the rate is sustained, the fetus appears compromised, or hydrops is present. Specialist assessment allows the team to balance rhythm control, maternal safety, gestational age, and neonatal preparedness while keeping the family informed at every stage.